Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$22.83 USD
+0.25 (1.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $22.67 -0.16 (-0.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JANX 22.83 +0.25(1.11%)
Will JANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
JANX Stock Hits Record High on Prostate Cancer Study Data
Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for JANX
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight
Janux Therapeutics GAAP EPS of -$0.55
Janux Therapeutics reports Q2 EPS (55c), consensus (47c)
Janux Therapeutics Inc (JANX) Announces First Patient Dosed in Merck Collaboration | JANX stock news